Shares of Novo Nordisk (NVO) have hit a record high on phase 1 trial data from Amycretin, its latest weight loss product. The new drug shows over 13% weight loss in users after 12 weeks of use, mor...

Novo Nordisk said on Thursday it expects Wegovy to be approved for sale in China this year and plans to soon launch the popular weight-loss drug in the largest Asian market with capped volumes.

Novo Nordisk's global obesity drug rollout will be dominated by its injectable medicines, while its oral version will be introduced later in higher priced markets, the company's Chief Executive Lar...

Novo Nordisk A/S (NYSE:NVO) stock is gapping to record highs today, after the pharmaceutical company reported positive phase 1 trial results for its experimental weight-loss drug, amycretin.

The company said its new treatment for weight loss, called Amycretin, appeared even more effective than its popular Wegovy drug in trials.

The American depositary receipts (ADRs) of Novo Nordisk A/S (NVO) gained more than 8% in early trading Thursday after the Danish maker of Ozempic and Wegovy released promising data on an experiment...

Novo Nordisk is now worth more than Elon Musk's electric vehicle giant Tesla, after shares of the Danish maker of Ozempic surged following the release of promising results for an oral weight loss t...

Novo Nordisk (NYSE: NVO ) stock is soaring higher on Thursday after the pharmaceutical company announced results from a weight loss drug clinical trial. The big news here is the company's oral weig...

Novo Nordisk (NYSE:NVO) unveiled a potential game changer during its Capital Markets Day with data on experimental obesity pill amycredtin potentially outperforming blockbuster drug Wegovy. An earl...

Shares of Danish pharma giant Novo Nordisk soared to a record high on Thursday after it reported promising data on a new weight loss pill, a sign of the company's plans to cement its prime position...

Novo Nordisk , maker of obesity drug Wegovy, on Thursday said it would present early-stage trial data for its highly anticipated pipeline drug, amycretin, for treatment of Type 2 diabetes.

Novo Nordisk (NVO) declines 3% despite achieving the primary endpoint with statistical significance in the FLOW outcomes study evaluating the efficacy of Ozempic 1 mg to treat CKD indication.

A clinical trial of semaglutide studying its ability to prevent kidney disease-related events was published. The study met its primary endpoint, but many observers were expecting better results.

Viking Therapeutics' weight loss candidate produced positive phase 2 results. The drug could eventually be a challenger to Novo Nordisk's Wegovy.

Novo Nordisk (NYSE:NVO) said diabetes patients have been able to prevent the onset of chronic kidney disease in trials of semaglutide, which it sells under the Ozempic and Wegovy brands. The Danish...